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Multiple Developmental Stage±Specific Enhancers
Regulate CD8 Expression in Developing Thymocytes
and in Thymus-Independent T Cells
the functional programs of T cells (Chan et al., 1994;
Corbella et al., 1994; Robey et al., 1994), there is a strong
likelihood that factors regulating the expression of CD4
or CD8 are also involved in directing DP thymocytes
toward the helper or cytotoxic lineage, respectively.
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Therefore, it is important to understand how the CD4³Howard Hughes Medical Institute
and CD8 genes are transcriptionally regulated during TNew York University Medical Center
cell development and to identify cis- and trans-actingNew York, New York 10016
elements involved in their regulation.
Within the last several years, the major cis-regulatory
elements directing expression of CD4 have been identi-Summary
fied. A T cell±specific enhancer located approximately
13 kb upstream of the transcriptional start site (SawadaWe and others have recently identified a CD8 locus
and Littman, 1991) directs expression of CD4 in bothenhancer (E8I) that directs expression in mature CD8
CD41CD82 (CD41) and CD42CD81 (CD81) T cells, whilesingle-positive thymocytes and peripheral CD81 T cells
subset specificity is achieved through silencing of CD4and in extrathymically derived intestinal intraepithelial
transcription in CD81 T cells by elements located in thelymphocytes (IEL). In this study, we show that deletion
first intron of the CD4 gene (Sawada et al., 1994; Siu etof E8I by homologous recombination results in re-
al., 1994; Donda et al., 1996).duced CD8aa homodimer expression on IEL. Since
The characterization of cis-elements that regulate ex-CD8 expression on thymus-derived T cells was normal,
pression of CD8 is still at an early stage. Thymus-derivedother enhancers regulate CD8 expression in these
CD81 T cells express heterodimers of CD8a and CD8bcells. By exploiting a transgenic reporter expression
on their surface, while extrathymically derived intestinalassay, we identified three additional enhancers that
intraepithelial lymphocytes (IEL) and a subset of humandirected expression in diverse thymocyte subsets and
NK cells express CD8aa homodimers (Jarry et al., 1990;mature T cells but not in CD8aa1 IEL. The results sug-
Lefrancois, 1991; Moebius et al., 1991). IEL that expressgest that CD8a expression is primarily regulated by
CD8aa homodimers are of both the TCRab or TCRgdE8I in IEL and by the novel enhancers in the thymus- lineage, whereas IEL that express CD8ab heterodimers
dependent lineages.
are exclusively of the TCRab lineage. Thus, the expres-
sion of the CD8a and CD8b genes, which are linked at
Introduction a distance of about 36 kb on mouse chromosome 6
(Gorman et al., 1988), must be regulated both coordi-
Peripheral T lymphocytes of the helper or cytotoxic phe- nately and independently. As an approach toward identi-
notype express either the CD4 or CD8 coreceptor mole- fying regulatory elements for the CD8 genes in vivo,
cules, respectively, and develop in the thymus from a Hostert et al. (1997a) generated transgenic mice with a
common progenitor expressing both coreceptors. Dur- P1 clone containing 80 kb of genomic DNA encom-
ing a process known as positive selection, double-posi- passing the entire murine CD8 locus. Proper develop-
tive (DP) thymocytes that express a T cell receptor (TCR) mental stage- and lineage-specific expression of the
specific for major histocompatibility complex (MHC) transgenic CD8 reporter was achieved, indicating that all
class I develop into CD8 single-positive (SP) thymo- major elements are localized within this large genomic
cytes, whereas those specific for MHC class II develop fragment. Similar results were reported for the human
into CD4 SP cells. After completing maturation, SP thy- CD8b gene in transgenic mice containing a 95 kb geno-
mocytes leave the thymus and constitute the thymus- mic fragment surrounding the human CD8b locus (Kief-
dependent peripheral T cell pool (Kisielow and von fer et al., 1997). By performing DNase I hypersensitivity
Boehmer, 1995; Zuniga-Pflucker and Lenardo, 1996; (DH) studies on the CD8 locus and testing genomic frag-
Marrack and Kappler, 1997). ments containing DH sites for enhancer activity, we and
The molecular mechanisms that regulate the develop- others have recently identified cis-regulatory elements,
mental choice between helper and cytotoxic lineage are within a 7.6 kb genomic BamHI fragment, that are in-
not known (Davis and Littman, 1994; von Boehmer, volved in the regulation of murine CD8 gene expression
1996). Recently, it was shown that transgenic overex- in vivo (Ellmeier et al., 1997; Hostert et al., 1997b). It
pression of an activated form of Notch favors T cell was shown that the E8I enhancer (initially designated
development toward the CD8 lineage, suggesting that E8SP) directs expression of a transgenic reporter gene in
the Notch pathway might be involved in lineage commit- peripheral CD81 T cells and mature CD8 SP thymocytes
ment of DP thymocytes (Robey et al., 1996). However, but not at earlier stages of T cell development (e.g.,
the involvement of known molecular targets of Notch in DP thymocytes). Furthermore, the onset of enhancer
thymocyte lineage commitment has not been shown. activity correlated with the final steps of positive selec-
Because there is coupling of coreceptor expression and tion, indicating a developmental stage±specific regula-
tion of its activity. In addition, we showed that E8I, which
is located approximately 16 kb upstream of the CD8a§ To whom correspondence should be addressed (e-mail: ellmeier@
saturn.med.nyu.edu) gene, directs expression of the reporter gene also in
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extrathymically derived IEL, thus indicating its specific- To exclude that the expression of CD8 in the absence
of E8I is influenced by the neomycin expression cassetteity toward the CD8a gene (Ellmeier et al., 1997). How-
ever, the identity of enhancer(s) that regulate expression due to transcriptional interference as observed by oth-
ers (Sleckman et al., 1996), heterozygous E8I 1/N miceof CD8 in DP thymocytes remained unknown.
In an effort to study E8I in more detail, we deleted the were crossed with transgenic mice expressing Cre re-
combinase under the control of the CMV promoterenhancer in embryonic stem (ES) cells by homologous
recombination. This experimental approach was de- (White et al., 1997). Heterozygous E8I 1/D mice (with
the deletion of the neomycin gene) were then interbredsigned to confirm the proposed role of this enhancer in
CD8 SP cells and IEL, and, additionally, to determine if to obtain E8I 1/1, 1/D, and D/D mice.
it could also have a role in the regulation of CD8 expres-
sion in DP thymocytes (e.g., by interacting cooperatively Normal T Cell Development in Mice Lacking E8Iwith another cis-element that together with E8I forms a It has been shown that in transgenic mice the 7.6 kb
DP-specific enhancer). We show that E8I is the primary genomic BamHI fragment was sufficient to drive expres-
enhancer regulating the expression of CD8a in the thy- sion of a reporter gene in mature CD8 SP thymocytes
mus-independent subsets of IEL of the gut. IEL from and peripheral CD81 T cells (Ellmeier et al., 1997; Hostert
mice lacking E8I showed a dramatic decrease of CD8aa et al., 1997b). This suggested that the enhancer regu-
homodimer expression levels (both on TCRab and lates the expression of CD8 after the final maturation of
TCRgd IEL) and the majority of TCRgd IEL lacked ex- the CD8 lineage. However, as shown in Figure 2B, the
pression of any CD8aa homodimers. In contrast to thy- absence of E8I had no effect on the expression of CD8mus-independent T cells, the deletion of E8I had no (both CD8a and CD8b expression levels were normal;
appreciable effect on CD8 expression in thymus-derived see Table 1) and on the appearance of CD81 T cells in
lymphocytes. Neither the appearance of peripheral the periphery. Lymph node or splenic (data not shown)
CD81 T cells nor the development of thymocytes was CD81 T cells from the knockout mice displayed normal
compromised in animals lacking E8I, indicating that levels of CD8 expression, and the ratio of CD41 to CD81
other enhancers are involved in the regulation of CD8 T cells was unchanged (2.6 6 0.5 and 3.1 6 0.5 in wild-
expression in mature T cells. We identified such addi- type littermates and E8I-deficient mice, respectively;tional enhancers, including one specific for DP thymo- n 5 6). In addition, loss of E8I activity did not interferecytes, by analyzing reporter gene expression in trans- with the development of DP and CD8 SP thymocytes,
genic mice. These enhancers directed expression of the indicated by the normal proportion of DP and CD4 or
human CD2 (hCD2) reporter at specific stages of T cell CD8 SP thymocytes (Figure 2A). Although the expres-
development and most likely compensate for E8I activity sion level of CD8 on peripheral T lymphocytes and DP
in E8I-null mice. However, none of these enhancers di- thymocytes was normal, CD8 SP thymocytes (TCRabhi)
rected expression of the reporter in CD8aa homodimer- from the knockout animals displayed a 10%±20% de-
expressing IEL, thereby explaining the dramatic reduc- crease in the level of CD8 expression compared to wild-
tion of CD8a expression in IEL of E8I2/2 mice. type littermate controls (Table 1). The expression pattern
of CD8 in the knockout mice did not differ between
animals with or without the deletion of the neomycinResults
expression cassette (D/D and N/N mice in Figure 2,
respectively). Therefore, the absence of E8I does notDeletion of the E8I Enhancer by influence the expression of CD8 in thymus-derived pe-Homologous Recombination
ripheral T cells. This clearly indicates that other cis-The mature and peripheral CD81 T cell enhancer E8I regulatory elements (either specific for CD8a or CD8b(Ellmeier et al., 1997; Hostert et al., 1997b) is located
or both) compensate for loss of E8I enhancer activityapproximately 16 kb upstream of the CD8a gene (Figure
and/or are involved in the regulation of CD8 gene ex-1A). To delete the enhancer by homologous recombina-
pression in mature CD8 SP thymocytes and peripheraltion, we prepared a targeting construct in which the 7.6
CD81 T cells.kb genomic BamHI fragment containing E8I (including
the two DNase I hypersensitivity sites HS-1 and HS-2)
was replaced by a neomycin resistance gene flanked CD8aa Homodimer Expression on Gut Intraepithelial
Lymphocytes Is Dramatically Reducedby two loxP sites (Figure 1B). Homologous recombina-
tion was performed in E14.1 ES cells (Kuhn et al., 1991) in Mice Lacking E8I
Intraepithelial lymphocytes from the gut generally be-and several targeted clones were isolated (designated
1/N; Figure 1C). Two 1/N ES cell clones were selected long either to the TCRab or TCRgd T cell lineage. IEL
of TCRab lineage express either CD8ab heterodimersfor injection into C57BL/6 blastocysts and chimeric mice
obtained from both clones were backcrossed either to or CD8aa homodimers, whereas TCRgd-positive IEL ex-
press CD8aa homodimers only. It is believed that IELC57BL/6 or AKR1 mice. The targeted allele was transmit-
ted to the offspring, which were subsequently interbred that express CD8aa homodimers (either of TCRab or
TCRgd lineage) develop extrathymically, whereas theto obtain E8I 1/1, 1/N, and N/N mice. There were no
significant phenotypic differences between F1 inter- origin of CD8ab heterodimer-expressing IEL remains a
matter of some controversy (Poussier and Julius, 1994;crosses from either of the two ES clones or from the
AKR1 and C57BL/6 backcrosses, and therefore we will Rocha et al., 1995; Klein, 1996). We have shown pre-
viously that E8I directs expression of a transgenic re-not distinguish between the clones and between the
different strains. porter gene in intraepithelial lymphocytes. Expression
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Figure 1. Deletion of the E8I Enhancer by Ho-
mologous Recombination
(A) Schematic representation of the CD8 lo-
cus. Horizontal arrows indicate the transcrip-
tional orientation of the CD8b and CD8a
genes. Vertical arrows indicate the two
DNase I hypersensitivity sites constituting the
E8I enhancer (Ellmeier et al., 1997; Hostert et
al., 1997b). BamHI sites (B) representing the
border of the targeted 7.6 kb genomic frag-
ment are shown.
(B) Schematic map of the targeting construct
(top part), the CD8 intergenic region before
and after homologous recombination (upper
and lower middle part), and the genomic lo-
cus after Cre-mediated deletion of the neo-
mycin resistance gene (bottom part). Only re-
striction sites important for the targeting
strategy are shown, except for BamHI (B). The
horizontal thick black line (in the top part,
lower middle part, and bottom part) indicates
the region of homology between the targeting
construct and the endogenous locus. The
bars with asterisks (in the upper middle part)
represent the 59 and 39 probes used for
Southern blotting to detect homologous re-
combination. Triangles in the top, lower mid-
dle, and bottom part indicate loxP sites. Solid
lines labeled PCR-1, PCR-2 (lower middle
part), and PCR-3 (bottom part) indicate the
expected PCR fragments after homologous
recombination (PCR-1) and before or after
neo deletion (PCR-2 or PCR-3, respectively).
Horizontal bars with numbers (indicating the
size in kb) represent the expected genomic
fragments after digestion with the appro-
priate restriction enzymes (XhoI and SalI for
the 59 targeted region; KpnI and XbaI for the
39 targeted region).
(C) Southern blot of KpnI/XbaI-digested DNA
isolated from a wild-type ES cell clone (1/1),
from ES cell clones after homologous recom-
bination (1/N), and from an ES cell clone after Cre recombinase-mediated deletion of neomycin (1/D). Deletion of the neomycin gene in mice
was detected by PCR (PCR-3 fragment) and by Southern blotting with a probe specific for neomycin (data not shown). Only the blot hybridized
with the 39 probe is shown. The origin of the detected fragments is indicated in (B).
of the hCD2 reporter was observed in all subpopulations N/N or D/D) were isolated and analyzed for the expres-
sion of CD8a on subpopulations expressing eitherof IEL, including CD8aa1 IEL of both the TCRab and
TCRgd lineage (Ellmeier et al., 1997). Therefore, IEL from TCRab or TCRgd. In contrast to thymocytes and lymph
node T cells, IEL displayed a dramatic reduction in CD8aeither wild-type or homozygous knockout mice (either
Figure 2. Normal CD8 SP T Cell Development
and CD8 Expression in Mice Lacking E8I
(A) Two-color flow cytometry analysis of CD4
and CD8 expression on thymocytes isolated
either from 1/1 and N/N littermates (upper
panel) or from 1/1 and D/D littermates (lower
panel). Numbers in the dot plot quadrants
indicate the percentage (of total gated thymo-
cytes) of the corresponding thymocyte sub-
populations.
(B) Lymph node T cells isolated from mice
of the indicated genotype were analyzed by
two-color flow cytometry analysis for expres-
sion of CD4 and CD8. Gates show the area
of either CD41 or CD81 T cells. Littermates
were analyzed both for 1/1 and N/N (upper
panel) and for 1/1 and D/D (lower panel) ge-
notypes.
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Table 1. Relative Reduction of CD8a Expression Levels on Different T Cell Populations in E8I-Deficient Mice
CD8aa1 IEL (n 5 7) CD8ab1 IEL (n 5 7) Thymocytes (n 5 6) CD81 LN T Cells (n 5 6)
TCRgd1a TCRab1 TCRab1 DP CD8 SP CD8a CD8b
3.64 6 0.7 2.26 6 0.4 1.45 6 0.3 1.02 6 0.1 1.37 6 0.1 1.02 6 0.1 1.00 6 0.1
Numbers indicate n-fold reduction of CD8a expression levels on the indicated T cell populations in E8I knockout mice relative to wild-type
littermate controls. To determine the expression levels of CD8a on DP or CD8 SP thymocytes, cells were gated on CD41TCRab2/int or
CD42TCRabhi populations, respectively. For CD81 LN T cells, relative reduction of expression levels for both CD8a and CD8b is shown.
a Only 25%±50% of TCRgd1 IEL in E8I-deficient mice expressed CD8aa homodimers compared to 80%±90% in wild-type littermate controls.
expression upon deletion of the E8I enhancer. As shown panel; Table 1). These results indicate that E8I is a major
cis-regulatory element for CD8a expression in these di-in Figure 3A, a 3- to 5-fold reduction in CD8a expression
levels was observed for TCRgd1 cells (Table 1). Further- verse IEL populations.
more, the percentage of TCRgd1 IEL that also expressed
CD8aa homodimers was reduced from about 80%±95%
in wild-type mice to 20%±50% in N/N and D/D mice Identification of Additional T Cell±Specific
Enhancers in the CD8 Locus(Figure 3A). Thus, deletion of E8I resulted in a significant
decrease in the level of CD8a on TCRgd lineage IEL as The results from the E8I enhancer deletion indicated
that other cis-regulatory elements are involved in thewell as a major reduction in numbers of CD8aa1TCRgd1
T cells. A similar, although less dramatic, reduction (1.5- regulation of CD8. However, other enhancers are only
able to fully compensate for the mature CD81 T cell±to 3-fold; Table 1) of CD8a expression was observed on
CD8aa1TCRab1 IEL (Figure 3B, upper panel). CD8ab specific enhancer in thymically derived T cells but not in
extrathymically derived CD8aa homodimer-expressingheterodimer-expressing IEL also displayed significantly
lower levels of CD8a on their surface (Figure 3B, lower IEL. To identify cis-regulatory elements involved in CD8a
Figure 3. Reduced Expression of CD8a on
Intestinal IEL in the Absence of E8I
(A) Expression of CD8aa homodimers on IEL
of the TCRgd lineage. A representative gate
for the TCRgd1CD8b2 population is shown.
Bars in the histograms indicate IEL defined
as being positive for CD8aa expression. The
number above the marked regions indicates
the percentage of CD8aa1 cells within the
gated population and the number in brackets
indicates the mean fluorescence of CD8aa
expression levels. Wild-type littermate con-
trols are shown above the histograms of N/N
or D/D mice.
(B) Expression of CD8a on IEL of the TCRab
lineage. Representative gates for the TCRab1
CD8b2 (upper panel) and the TCRab1CD8b1
populations (lower panel) are shown in the
dot plots. The numbers above the marked
regions in the upper panel indicate the per-
centage of CD8aa-positive cells within the
gated population and the mean fluorescence
of CD8aa expression levels (in brackets), re-
spectively. The number (in brackets) above
the marked region in the lower panel indicates
the mean fluorescence of CD8a expression
on CD8ab heterodimer-expressing TCRab
IEL. Wild-type littermate controls are shown
above the histograms of N/N or D/D mice.
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and/or CD8b gene expression, we extended the experi- enhancer (designated E8II) that is active in both immature
DP thymocytes and mature CD8 SP thymocytes and Tmental approach used to identify E8I (Ellmeier et al.,
1997). In brief, a hCD2 reporter gene was cloned down- cells.
Because TG-23 displayed the same expression pat-stream of the CD8a promoter and genomic fragments
containing putative cis-regulatory elements were in- tern as TG-21, we expected that TG-31 (generated with
a 4.1 kb genomic EcoRI/BamHI fragment) would notserted upstream of the CD8a promoter and tested for
their ability to direct expression of the reporter gene in contain any regulatory activity. Surprisingly, TG-31 di-
rected hCD2 expression only on immature DP thymo-thymocytes and T cells of transgenic mice. We took
advantage of the published hypersensitivity map of the cytes and not on CD4 or CD8 SP thymocytes (Figure
4A). To determine the developmental stage at whichCD8 locus (Hostert et al., 1997a) and generated a
transgenic construct (TG-21) with a 15 kb genomic frag- hCD2 expression ceased during the development of
CD8 SP thymocytes, TCRab expression levels werement containing several DH sites around the 39 end of
the CD8b locus (see Figure 4D). This and other con- compared between hCD2-positive and hCD2-negative
cells within the intermediate CD4loCD81 population (Fig-structs described below were injected into (B6/D2) F2
mouse eggs to generate transgenic animals. Transgenic ure 6C; see Figure 6A for gating areas). The majority of
hCD2-positive CD4loCD81 cells displayed intermediatefounders identified by Southern blotting were either ana-
lyzed directly or backcrossed to C57BL/6 mice to gener- levels of TCRab (only 21.3% of cells expressed high
levels of TCRab), indicating that they were still imma-ate transgenic lines that were then analyzed.
The expression pattern of the hCD2 reporter in TG-21 ture (Bendelac et al., 1992). In contrast, hCD2-negative
cells showed a higher percentage of cells (44.5%) ex-transgenic founders or lines reflected the developmental
subset- and lineage-specific expression pattern of the pressing high levels of TCRab (Figure 6C). Since expres-
sion of hCD2 was variegated in TG-31 (approximatelyendogenous CD8 gene. During thymocyte development,
hCD2 was expressed both in the DP and in the CD8 SP 75% of DP cells expressed hCD2; see Figures 4A and
6A), some hCD2-negative cells within the CD4loCD81thymocyte population but not in CD4 SP thymocytes
(Figure 4A). Furthermore, hCD2 expression was ob- population are of immature phenotype. This might ex-
plain why not more than 44.5% of thymocytes within theserved on peripheral CD81 T cells but not on CD41 cells
(Figure 4B). No expression of hCD2 was found on B hCD2-negative CD4loCD81 population expressed high
levels of TCRab. Consistent with the downregulation ofcells (data not shown). We observed position effect var-
iegation of TG-21 expression, as shown previously for hCD2 expression at the TCRint/hi to TCRhi transition during
CD8 SP thymocyte development, no hCD2 expressionthe E8I enhancer (Ellmeier et al., 1997; Hostert et al.,
1997b). This is in agreement with the putative absence was observed on lymph node CD81 T cells (Figure 4B).
The enhancer activity within this fragment was desig-of a locus control region within the CD8 locus (Hostert
et al., 1997a). nated E8III.
During the process of mapping enhancers around theTo determine whether this newly identified enhancer
directs expression also in CD8aa1 cells, IEL from the CD8b locus we also analyzed TG-22 and TG-25, which
contained additional 3.2 kb of genomic sequence 59 togut mucosa of TG-21 transgenic animals were isolated
and analyzed for the expression of hCD2. As shown in the TG-31 fragment (see Figure 5D). Expression of hCD2
in transgenic mice generated with these constructs wasFigure 4C, CD8aa homodimer-expressing IEL (of both
TCRgd and TCRab lineages) did not express hCD2. In observed not only in CD81 T cells but also in the CD41
T cell lineage (Figure 5A). The percentage of hCD21 cellscontrast, hCD2 was detectable on CD8ab heterodimer-
expressing IEL, although the percentage of hCD21 cells within the CD41 T cell compartment was always lower
than in the CD81 T cell population in all transgenic found-within the CD8ab1 IEL was significantly lower than in
CD8ab1 lymph node T cells (as shown in Figure 4B), ers and established lines (Figure 5A). However, the num-
ber of CD41 T cells expressing hCD2 corresponded pro-indicating that the enhancer may have only weak activity
in CD8ab1 IEL. These results therefore indicate that portionally to the percentage of hCD2-expressing CD81
T cells. Since five hCD2-expressing founders for TG-22this enhancer functions specifically in T cells expressing
CD8ab heterodimers but not CD8aa homodimers. and three founders for TG-25 (see Table 2) displayed this
broader expression pattern (directed by an enhancer
activity designated E8IV), it is unlikely that this is medi-
Identification of a Double-Positive ated by position effect variegation due to the site of
Thymocyte-Specific Enhancer transgene integration. Expression of hCD2 was also ob-
To narrow down the region within TG-21 that is involved served in DP thymocytes in TG-22 mice (Figure 5B; Table
in mediating the expression of hCD2 in CD8ab homodi- 2) and in CD8ab heterodimer-expressing IEL but not in
mer-expressing cells, transgenic constructs (TG-23 and CD8aa1 IEL (Figure 5C).
TG-31) containing smaller genomic fragments were gen-
erated (Figure 4D). TG-23, containing a 4.3 kb genomic
BamHI fragment, mediated expression of hCD2 in a pat- Summation of Enhancer Functions
during Developmenttern indistinguishable from TG-21. Expression of hCD2
was observed in DP and CD8 SP thymocytes and in In mice prepared with TG-22, the hCD2 reporter was
consistently expressed at higher levels on DP than onperipheral CD81 T cells (Figures 4A and 4B). Within the
IEL T cell population, hCD2 was detected only on a small CD4 or CD8 SP thymocytes (Figures 5B and 6A). This
suggests that there is a developmental stage±specificpercentage of CD8ab1 but not on CD8aa homodimer-
expressing cells (Figure 4C). Thus, TG-23 contains an change or transition in the activities of the E8III and/or
Immunity
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Figure 4. Expression of the hCD2 Reporter in T Lymphocyte Subsets of Transgenic Mice Generated with Constructs TG-21, 23, and 31
(A) Three-color flow cytometry analysis on thymocytes isolated from the transgenic mice indicated. Dot plot shows representative gates for
the CD42CD82, CD41CD81, CD41CD82, and CD42CD81 thymocyte populations. Individual histograms show hCD2 expression on gated
thymocyte populations (gates are indicated in the upper right of each histogram).
(B) Lymph node T cells were isolated from the indicated transgenic mice and analyzed by three-color flow cytometry for expression of CD4,
CD8, and hCD2. Dot plot shows representative CD41 and CD81 T cell gates used for the histograms shown below.
(C) Intestinal intraepithelial lymphocytes isolated from transgenic mice TG-21, TG-23, a nontransgenic control mouse, and a transgenic positive
control mouse generated with construct TG-8 (containing HS-2 of the E8I enhancer) were analyzed for expression of CD8a, CD8b, and hCD2.
Representative gates for CD8aa homodimer- and CD8ab heterodimer-expressing cells are shown in the dot plot. Histograms below show
hCD2 expression on gated CD8aa1 or CD8ab1 IEL.
(D) Schematic map of the genomic fragments used for the generation of the transgenic constructs TG-21, TG-23, TG-31, and TG-8. The
location of DH sites (indicated by vertical arrowheads) is according to Hostert et al. (1997a). HS-1 and HS-2 represent the CD81 T cell line-
specific DH sites constituting the E8I enhancer described earlier (Ellmeier et al., 1997). The transcriptional orientation of the CD8b gene is
indicated by the horizontal arrow. Restriction enzyme sites are BamHI (B), EcoRI (E), and HindIII (H).
E8IV enhancers. It was previously shown that DP thy- levels of hCD2 were examined within these different
CD81 developmental stages. As shown in Figure 6A, amocytes undergoing positive selection partially downmod-
ulate surface expression of CD8 and CD4. Then, in the progressive decrease to lower levels of hCD2 expres-
sion was observed during CD8 lineage development. Topresence of MHC class I ligand, they progress through
a CD4loCD81 stage toward the mature CD42CD81 stage examine this further, the developmental stage of thymo-
cytes expressing high or low levels of hCD2 within thein which they display high levels of TCR and low levels of
HSA (van Meerwijk and Germain, 1993). The expression intermediate CD4loCD81 population was determined by
Developmental Stage±Specific CD8 Enhancers
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Figure 5. A T Cell±Specific Enhancer from the CD8b Locus Directs Expression of hCD2 in Both CD41 and CD81 T Lymphocytes
(A) Three-color flow cytometry analysis of peripheral blood lymphocytes isolated from TG-22 and TG-25 founders or lines. Representative
gates for CD41 and CD81 T cells are shown in the dot plot. Histograms show expression of hCD2 on either CD41 or CD81 T cells.
(B) Thymocytes from a TG-22 mouse (founder #20) were analyzed by three-color flow cytometry. Gates for the CD42CD82, CD41CD81,
CD41CD82, and CD42CD81 thymocyte populations are shown in the dot plot. Histograms show expression of hCD2 on different thymocyte
subsets (indicated in the upper right of each histogram).
(C) Intestinal intraepithelial lymphocytes isolated from TG-22 (founder #20) were analyzed for expression of CD8a, CD8b, and hCD2. Gates
for CD8aa homodimer- and CD8ab heterodimer-expressing cells are shown in the dot plot. Histograms show hCD2 expression on gated
CD8aa1 or CD8ab1 IEL.
(D) Schematic map of the genomic fragments used for transgenic constructs TG-22, TG-25, and TG-31. The location of DH-sites (indicated
by arrowheads) is according to Hostert et al. (1997a). The transcriptional orientation of the CD8b gene is indicated by the horizontal arrow.
Restriction enzyme sites are BamHI (B) and EcoRI (E).
analyzing the expression levels of HSA, TCRab, and CD69 et al., 1997). In contrast, CD4loCD81 cells expressing
lower levels of hCD2 displayed the HSAloTCRabhi pheno-(Figure 6B). Thymocytes expressing higher levels of
hCD2 were of the immature phenotype (HSAhiTCRabint) type that characterizes mature cells. These results sug-
gest that the expression of hCD2 in TG-22 mice is gov-and some of the cells expressed high levels of CD69, indi-
cating that they already received the signal for selection erned by the summation of the activities of E8III (high
expression in DP cells that ceases at the HSAhiTCRabint/hi(Bendelac et al., 1992; Swat et al., 1993; Merkenschlager
Table 2. Expression of hCD2 on Different T Cell Subsets in Transgenic Mice
Peripheral
Lymphocytes Thymocytesa Intestinal IELa
TG Founders CD41 CD81 DP CD4 SP CD8 SP CD8aa CD8ab
21 6 (8) 2 1 1 2 1 2 1/2
22 5 (5) 1 1 1 1 1 2 1
23 4 (9) 2 1 1 2 1 2 1/2
25 3 (4) 1 1 nd nd nd nd nd
31 0 (3) 2 2 1 2 2 nd nd
Summary of hCD2 expression in mice generated with the different transgenic constructs (TG-21, 22, 23, 25, and 31). The first number next
to the transgenic construct indicates how many founders were expressing hCD2 in CD81 PBLs, while the second number (in brackets) indicates
the total numbers of founders obtained. 1, 1/2, or 2 below the different T lymphocyte populations indicates expression, weak expression,
or no expression of hCD2, respectively, on this particular subset in transgenic founders or lines. nd, not determined.
a Only three founders generated with TG-21 and two founders from TG-22 or 23 were analyzed for expression of hCD2 on thymocytes or IEL.
For TG-31, only thymocytes isolated from two founders were analyzed for hCD2 expression.
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Figure 6. Developmental Stage±Specific Regulation of Enhancer Function during CD8 SP Thymocyte Development
Thymocytes isolated from mice generated with TG-22 (founder #20) or TG-31 (founder #9) were analyzed by four-color flow cytometry for the
expression of CD4, CD8, hCD2, and TCRab, CD69, or HSA.
(A) Histograms showing hCD2 expression levels on different subpopulations of CD8-expressing thymocytes. Representative gating areas for
the CD41CD81, CD4loCD81, and CD42CD81 populations are shown in the dot plot on the left. Human CD2-high (hi) and hCD2-low (lo) regions
in the CD4loCD81 histogram for TG-22#20 indicate representative gates used for further analysis in Figure 6B, while hCD2-negative (neg) and
hCD2-positive (pos) regions in the CD4loCD81 histogram for TG-31#9 indicate gates used for further analysis in Figure 6C.
(B) Expression of TCRab, CD69, and HSA (left, middle, and right column, respectively) on total CD4loCD81 thymocytes (upper panel) and
subsets of this population from TG-22#20 that express either high (middle panel) or low (lower panel) levels of hCD2, as defined in Figure 6A.
(C) Expression of TCRab on total CD4loCD81 thymocytes (upper panel) and subsets of this population from TG-31#9 that are either positive
(middle panel) or negative (lower panel) for hCD2 expression, as defined in Figure 6A.
to HSAloTCRabhi transition; see also Figure 6C) and E8IV lineages. Because expression of the closely linked CD8a
and CD8b genes is likely to be coordinately regulated(lower expression in SP cells) during thymocyte differen-
tiation. Alternatively, it is possible that E8IV is active in in thymus-dependent T cells, we believe that E8I repre-
sents an enhancer specific for CD8a expression in IEL.DP cells as well and that the observed reduction of hCD2
expression during maturation of the CD8 lineage is due Additional T cell±specific enhancers identified near and
within the 39 end of the CD8b gene, designated E8II, E8III,to extinguishing E8III enhancer activity (Figure 6C). Addi-
tional studies with transgenic constructs containing E8IV and E8IV, displayed developmental stage- and lineage-
specific activities within the thymic-dependent T cellalone are required to determine if E8IV is also active in
DP thymocytes. compartment but had no activity in the CD8aa1 IEL.
These novel enhancers are likely to function specifically
in thymocyte differentiation and may regulate expres-Discussion
sion of CD8a, CD8b, or both. The results of this study
thus reveal a remarkable diversification in lineage-spe-In this study, we have used gene targeting to show that
the CD8 enhancer E8I has a major role in regulating cific regulation of CD8 gene expression by differential
utilization of several closely linked cis-elements.CD8aa homodimer expression in IEL. Previous studies
had shown that E8I directs transgenic reporter gene
expression both in mature CD8 SP thymocytes and The Role of E8I in Thymus-Derived T Cells
It has been shown that E8I is sufficient to direct expres-CD81 T cells (Ellmeier et al., 1997; Hostert et al., 1997b)
and in extrathymically derived IEL (Ellmeier et al., 1997). sion of a reporter gene in mature CD8 SP thymocytes
and in CD81 T cells, although these studies did notHowever, targeted deletion of this enhancer had no ef-
fect on development of the mature thymus-derived T reveal whether E8I is the only enhancer regulating ex-
pression of CD8 in mature T cells. However, the tightcells, yet resulted in a dramatic reduction in the expres-
sion of CD8a in CD8aa1 IEL of both TCRab and TCRgd correlation between onset of E8I activity with the final
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steps of positive selection indicated a developmental
stage±specific regulation of the enhancer and sug-
gested an important role for E8I in the maturation of CD8
lineage thymocytes (Ellmeier et al., 1997; Hostert et al.,
1997b). Therefore, it was surprising that the deletion of
the enhancer did not affect the expression of CD8 and
the appearance of thymus-derived CD81 T cells in the
periphery. This might indicate that the behavior of the
enhancer in transgenic mice did not reflect E8I function
in the context of the endogenous chromosomal location.
This possibility cannot be ruled out, although we con-
sider this as rather unlikely since a defined develop-
mental stage±specific induction (at the HSAhiTCRint/hi to
HSAloTCRhi transition) of enhancer activity and CD8 sub-
set-specificity of E8I were observed in at least 19 inde-
pendent transgenic founders or lines (generated with
five different transgenic constructs). Instead, a more
favorable explanation would be that additional cis-regu- Figure 7. Function of Multiple Enhancers in CD8 Gene Regulation
latory elements are involved in regulating CD8 expres- (A) Schematic map of the CD8 locus and the location of the individual
sion in thymus-derived T cells and that these enhancers enhancers relative to the CD8a and b genes (arrows indicate the
are able to compensate for loss of E8I activity (see be- transcriptional orientation). All BamHI (B), but only relevant EcoRI
(E) restriction sites are shown. The exact location of E8II, E8III, orlow). This notion is supported by the observation that
E8IV within the B/B, B/E, or E/E fragments, respectively, is not known.mature CD8 SP thymocytes from E8I-deficient mice (ei-
Closed and open bars around the CD8b gene indicate CD8b codingther N/N or D/D) exhibited a 10%±20% reduction in the
and noncoding exons, respectively (Nakayama et al., 1989). The
level of surface CD8. mature CD81 T cell enhancer E8I can be divided into two enhancer
subregions designated E8I-A and E8I-B (based on the location of the
DNase I hypersensitivity sites and on transgenic reporter expression
studies; Ellmeier et al., 1997; Hostert et al., 1997b).The Role of E8I in Intestinal IEL
(B) Diagram summarizing the developmental stage-, subset- andCD8aa1 IEL (of both the TCRab and TCRgd lineage)
lineage-specificity of the individual enhancers in the indicated Tare primarily of extrathymic origin, whereas CD8ab1 IEL
lymphocyte populations. The developing CD8 single-positive thy-
(exclusively of the TCRab lineage) may require the thy- mocyte lineage (CD4lo/2CD81) is subdivided into TCRint/hiHSAhi and
mus for development (Poussier and Julius, 1994; Rocha TCRhiHSAlo populations. The shaded areas indicate enhancer activ-
ity, while the hatched area indicates only weak enhancer activity.et al., 1995; Klein, 1996). The expression of CD8aa ho-
nd, not determined.modimers on thymus-independent IEL was severely
compromised in E8I-deficient mice, and there was also
a modest decrease of CD8a levels in CD8ab1 IEL. Multiple Subset-Specific Cis-Regulatory Elements
TCRgd1 IEL displayed reductions in both CD8aa expres- in the CD8 Locus
sion levels (about 3- to 5-fold) and the percentage of The phenotype observed in E8I enhancer knockout micecells expressing CD8aa. The reason for loss of CD8aa indicated that there must be other cis-regulatory ele-
expression on most, but not all, E8I-null IEL is not known. ments that direct CD8 expression not only in immature
It is possible that there are sublineages of TCRgd IEL thymocytes but also in peripheral CD81 T cells. It has
that differ in their ability to employ one or more en- recently been shown (Hostert et al., 1997a) that several
hancers other than E8I for CD8a gene expression. Other DH sites are clustered (in a region designated cluster
enhancers may thus be able to partially compensate IV) around the CD8b gene. Transgenic mice prepared
in the CD8aalowTCRgd1 sublineage. Future comparative with a construct containing the DH sites from cluster IV
studies of the Vg and Vd usage by these IEL subsets in (in a 15 kb genomic fragment) directed reporter gene
E8I-knockout mice might help to reveal whether they expression in both immature DP thymocytes and mature
represent different sublineages. Alternatively, E8I may CD81 T cells. This result is consistent with a recent
be involved in establishing an open chromosomal con- finding that a 95 kb genomic fragment spanning the
figuration of the CD8a locus during extrathymic devel- human CD8b gene could direct expression of CD8b on
opment of TCRgd1 IEL, and its absence would result in DP thymocytes and mature CD8 SP T cells in transgenic
variegated expression of CD8a. mice (Kieffer et al., 1997).
TCRab IEL also displayed lower levels of CD8aa ho- In the process of mapping the cis-acting elements
modimers, although to a lower extent (2- to 3-fold). A within the 15 kb genomic fragment, we were able to
decrease in the proportion of TCRab1 cells expressing separate an enhancer activity (E8III) specific for immature
CD8aa homodimers was observed in some E8I-deficient thymocytes from another enhancer activity (E8II) that
mice. Nevertheless, the IEL phenotype in E8I-deficient mediated expression both in DP and in CD8 SP thymo-
mice clearly indicates that E8I contains major cis-regula- cytes (see summary in Figure 7). E8III directed expression
tory elements required for CD8a expression in this pre- of the reporter gene in DP thymocytes, but its activity
sumptive extrathymically derived lymphocyte popu- ceased during positive selection as indicated by a grad-
ual loss of hCD2 surface expression on thymocytes atlation.
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a later developmental stage (i.e., at the TCRabint/hi to cells and may therefore regulate expression of CD8a,
CD8b, or both. Studies on the regulation of the murineTCRabhi transition) and by the absence of hCD2 expres-
sion on peripheral T lymphocytes. It remains to be deter- HoxB cluster have recently demonstrated that some
promoters can either share or compete for the samemined whether there are physically separable DP and
SP enhancer activities within E8II. Further transgenic enhancer (Sharpe et al., 1998). Analyses on promoter
and enhancer interactions in Drosophila have alsoexpression studies will help to clarify this issue.
An additional level of complexity was revealed by the shown that compatibility between the interactions of
these cis-regulatory elements, regulated by propertiesfinding that a 3.2 kb genomic region from the CD8b
locus contains an enhancer activity (E8IV) that directs of the promoter region, is one way to achieve selectivity
of gene expression in ªgene-denseº areas (Li and Noll,expression of the hCD2 reporter not only in CD8 SP
thymocytes and CD81 T cells but also in the CD4 lineage. 1994; Merli et al., 1996; Ohtsuki et al., 1998).
Since the transgenic constructs in our studies utilizedThis observation is unlikely to be explained by position
effects due to transgene integration, since six indepen- the CD8a promoter, it is possible that some enhancers
identified in this study (if they are specific for CD8b)dent founders generated from two different constructs
(TG-22 and TG-25) containing the 3.2 kb fragment (in do not function properly in conjunction with the CD8a
promoter. Incompatibility of enhancer and promoteraddition to other genomic regions, see map in Figure 5D)
displayed this expression pattern of the hCD2 reporter combinations could also explain why the E8I enhancer,
which is specific for CD8a expression in extrathymically(Table 2).
It has recently been shown that CD8b is expressed derived IEL, does not act upon the CD8b gene and its
promoter, indicated by the absence of CD8b expressionat low levels in a subset of CD41 T cells, which would
be consistent with the possibility that E8IV represents in these T cells. Alternatively, boundary or insulator ele-
ments might be localized between the E8I enhancer andan enhancer specific for expression of CD8b in both
CD41 and CD81 T cells. Expression of a CD8a transgene the CD8b gene, thereby preventing E8I and CD8b pro-
moter interaction and subsequent expression of CD8bin the CD4 subset resulted in the appearance of about
25% mature CD41 T cells that also expressed CD8ab in IEL. Therefore, in future studies it will be important
to generate transgenic constructs in which identifiedheterodimers, while the majority of the other transgenic
CD4 cells expressed only CD8aa homodimers (Hostert enhancers are combined with a reporter gene driven by
the CD8b promoter. In addition, single or combinatorialet al., 1997a). The enhancer driving CD8b expression in
the CD4 lineage appears to be weak, since only a subset deletions of the enhancers by homologous recombina-
tion should help to determine the specificity of the indi-of CD41 T cells expressed low levels of the CD8b protein.
This may explain why hCD2 expression was consistently vidual enhancers.
The identification of several cis-acting elements fromobserved in a smaller proportion of CD4 SP cells than in
cells of the CD8 lineage, although the possibility remains the CD8 locus provides us now with the opportunity to
identify trans-acting factors that bind to these en-that there are additional cis-elements required for ex-
pression of CD8b in CD4 lineage cells. hancers. Since CD8 expression correlates with the cyto-
toxic program of T cells, this could also lead to the
identification of factors involved in directing a DP thymo-
Enhancer Activities and Lineage Commitment cyte into the cytotoxic CD8 lineage.
An implication of the finding of the mature CD8 enhancer
(E8I) was that there must exist other enhancers directing
Experimental ProceduresCD8 expression in immature thymocytes. Therefore, a
model was proposed suggesting that different cis-act-
Generation of the E8I Targeting Constructing elements are involved in regulating CD8 expression A genomic clone containing the enhancer region was isolated from
in immature and mature thymocytes and that a switch a 129 genomic library (Stratagene) and subcloned into pBluescript
(pBS; Stratagene) (Ellmeier et al., 1997). The short and the long armsin enhancer usage and activities occurs during the latest
of the targeting construct were isolated as a 1.1 kb BamHI/NotIstages of positive selection and CD8 lineage develop-
fragment (representing one end of the isolated genomic clone) orment. A prediction of this model is that different sets of
as a 5.6 kb AflII (blunted)/BamHI fragment, respectively. The shorttranscription factors may be involved in regulating CD8
and the long arms were sequentially cloned into a pBS-based vector
expression in immature and mature thymocytes, unless containing a polylinker with suitable cloning sites and the thymidine
the accessibility of the different enhancers changes dur- kinase gene driven by the herpes simplex virus enhancer/promoter
elements (Thomas and Capecchi, 1990). A polylinker containing aing development. The identification of additional CD8
SalI site was then cloned between the short and the long arm oflocus enhancers that display developmental stage±
the targeting construct and a 1.4 kb XhoI/SalI fragment containing aspecific activity supports this model, although some
neomycin resistance gene (driven by the thymidine kinase enhancer/enhancers may be active both in immature and mature
promoter) flanked by two loxP sites (Gu et al., 1993) was subse-
thymocytes. quently inserted into the SalI site. All cloning steps were performed
Our studies have not addressed the specificity of the according to standard procedures (Sambrook et al., 1989).
E14.1 ES cells (Kuhn et al., 1991) were transfected with 30 mgenhancers toward the CD8a and/or b genes and the
NotI-linearized targeting vector and cultured on mitomycin C±treatedclose proximity of the four different enhancers raises
murine embryonic fibroblasts. Two days after transfection, G418the question as to how T cell lineage-specificity of CD8a
(Geneticin, Gibco) was added to a final concentration of 350 mg/mlor CD8b expression is achieved. In contrast to E8I, which and after another 2 days gancyclovir (GANC) was added (2 mM final
directed expression in CD8aa1 IEL (Ellmeier et al., 1997) concentration) for negative selection. There was approximately 10-
and hence is likely to function in conjunction with the fold enrichment between plates with and without GANC. Nine days
post-transfection, individual ES cell colonies were isolated and halfCD8a promoter, E8II, E8III, and EIV function in CD8ab1
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of each colony was initially screened in pools of six by PCR analyses transgenic mice, Wojtek Auerbach for providing Cre recombinase
transgenic mice, and Steffen Jung and Yong-Rui Zou for comments(PCR product 1 in Figure 1). ES cell clones of PCR positive pools
were expanded, and correct targeting (both for the 59 and 39 end) on the manuscript. W. E. was supported by an Erwin-SchroÈ dinger
postdoctoral fellowship from the Fonds zur FoÈ rderung der wis-was confirmed by Southern blotting. Two targeted ES cell clones
were injected into E3.5 C57BL/6 blastocysts and transferred into senschaftlichen Forschung (Vienna, Austria) and is currently an as-
sociate of the Howard Hughes Medical Institute. D. R. L. is an investi-(B6/D2) F1 pseudopregnant females. Chimeric mice obtained were
then backcrossed to either C57BL/6 or AKR1 mice and transmission gator of the Howard Hughes Medical Institute.
of the targeted allele was confirmed by PCR and Southern blot
analyses of tail DNA.
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